Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Application Open: Springboard Enterprises 2019 Health Innovation Hub: Life Sciences
February 25, 2019
Women life science entrepreneurs: Springboard Enterprises is now accepting application for the 2019 Health Innovation Hub: Life Sciences track.
Springboard’s Health Innovation Hub: Life Sciences 2019 is a year-long program for women-led seeking growth funding and expert connections to develop solutions in healthcare, including new drugs, diagnostics, pharma technologies, treatments for rare diseases, and medical devices. Those selected for the program will be matched with a personal advisory team of experts and invited to participate in several in-person and virtual sessions, workshops, and presentation opportunities. Priority Deadline is March 1! Full information on the program can be found at sb.co/HIH
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2889
[post_author] => 3
[post_date] => 2017-12-01 20:57:05
[post_date_gmt] => 2017-12-01 20:57:05
[post_content] => Date: May 9, 10, 11, 2018
Accepting Applications: December 15, 2017 – Seating will be limited.
Unlocking the power of female leaders for a competitive and innovative future in STEM
Occupations in the fields of science, technology, engineering and mathematics are expected to continue to outpace non-STEM jobs over the next decade. Yet while women make up more than half of all workers with post-secondary degrees, only slightly more than a quarter of them are in core STEM fields. The Women in STEM Leadership Program encourages and equips women at all stages of their careers with the skills necessary to advance as productive and valuable employees in their chosen STEM fields.
Call 1-631-216-7518 or fill out the form below for detailed program information: Learn more & apply here.
[post_title] => Women in STEM Leadership Program
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => 2889-2
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-25 15:43:58
[post_modified_gmt] => 2018-01-25 15:43:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2889
[menu_order] => 133
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4426
[post_author] => 4
[post_date] => 2024-05-21 14:27:18
[post_date_gmt] => 2024-05-21 18:27:18
[post_content] =>
The Life Sciences Innovation and Entrepreneurship (LiSIE) program at Stony Brook is looking to give students a jump-start in the bioscience industry. The program is a joint effort between the Department of Biomedical Engineering in the College of Engineering and Applied Sciences, the College of Business and the Center for Biotechnology. “From the lab to leadership”, the program aims to teach key business principles to life sciences students so they’re equipped to work in the business side of science.
Read the recent SBU News feature on the program and the CFB Appointed Director Director of the Program in Life Sciences Innovation and Entrepreneurship, Dr. Louis A. Peña.
Join as AdvaMed presents “Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices” with MIDI Medical Device Development Corp. and Valencell, Inc. This webinar is presented by Christopher Montalbano, CEO, MIDI Medical Device Development Corp., and Ryan Kraudel, Vice President, Marketing, Valencell, Inc., this webinar will examine the way in which wearables advance public health when a strategic device development approach is utilized to integrate and harmonize: Lifestyle, IoMT, Biosensing, and Physiological Sensing.
In this AdvaMed Event, MIDI & Valencell will cover: • Understand how wearable IoMT devices utilizing Bio-Sensors and Physiological Sensors translate into enhanced healthcare and wellness lifestyles. • Learn how to optimize the selection of sensor (or sensor cluster) through a proven 4-Step approach of: User Experience Monitoring, Body Assessments, Key Body Metric Capture and Sensor Selection. • Learn the 3-Step Innovation Roadmap™ for optimized wearable device development including: Discovery Research™, MVP R&D and AGILE Commercialization under ISO-13485. • Review of Case Studies that demonstrate implementation of these innovation principles yielding advanced wearable IoMT healthcare sensing devices.
[post_title] => Webinar: Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices - September 15th
[post_excerpt] => On September 15 join as MIDI Medical Device Development Corp. AdvaMed, and Valencell, Inc. present “Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices”
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => webinar-advancing-public-health-with-wearables-strategic-development-of-iomt-biosensing-lifestyle-devices-september-15th
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-20 16:02:48
[post_modified_gmt] => 2021-09-20 16:02:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3814
[menu_order] => 38
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
